Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

So you think that the safety review of 30 subjects in the beginning of April was the planned interim analysis referenced on October 2, 2020 and that there's no reason to expect any further analysis until all 120 participants are dosed and the trial is completed. And that there will be no indication of efficacy until the study is complete.

I'm surprised.